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Introduction {#sec1}
============

Although the adult mammalian CNS has a limited capacity for regeneration, lost oligodendrocytes and the myelin they produce are restored during remyelination. In response to demyelination, oligodendrocyte progenitor cells (OPCs) proliferate and migrate to the lesion, where they differentiate into remyelinating oligodendrocytes ([@bib9], [@bib29]). Remyelination restores saltatory conduction and ensures axonal survival, and its impairment renders demyelinated axons vulnerable to irreversible degeneration ([@bib10]). Thus, promoting remyelination is a major therapeutic objective in chronic demyelinating diseases such as multiple sclerosis, where remyelination becomes increasingly inefficient with disease progression ([@bib11]).

Myelination during development is strictly coupled to angiogenesis ([@bib28]), where OPCs use the vasculature as scaffolds for migration ([@bib25]). Similarly, regeneration in the CNS is coupled to the vascular niche ([@bib19]). The CNS vascular niche consists of endothelial cells (ECs), vasculature-associated cells such as perivascular cells, astrocytes, neurons, OPCs, molecules derived from these cells, and blood-derived elements. Pericytes (PCs), which are located at the abluminal surface of capillaries and embedded within the basement membrane, regulate angiogenesis and neovascularization and control microvascular blood flow ([@bib2]). The CNS contains the highest PC density in the body, ensuring proper blood-brain barrier (BBB) structure and function ([@bib2], [@bib26]). CNS-resident PCs also share features with mesenchymal stem cells (MSCs), expressing similar genes and differentiating into cells of the mesenchymal lineage in vitro ([@bib7]). MSCs secrete a plethora of paracrine signaling molecules ([@bib4]), including factors that promote oligodendrocyte differentiation ([@bib14], [@bib24]). We hypothesized that PCs act in a similar fashion ([@bib15]). This assumption is supported by the close physical proximity between PCs and OPCs in healthy cerebral white matter ([@bib18]) and by the ability of PC-derived transforming growth factor β 1 to regulate OPC migration during cortical development ([@bib5]). Here we analyzed PCs, their response to a demyelinating lesion, and their functional role in oligodendrocyte differentiation during remyelination. In vivo relevance was studied through a genetic mouse model with reduced pericyte coverage. Moreover, molecular and cellular analysis identified the PC-derived factor modulating OPC differentiation.

Results {#sec2}
=======

Pericytes Respond to CNS Demyelination {#sec2.1}
--------------------------------------

We first analyzed the proliferative response and localization of ECs and PCs following induction of white matter demyelination upon injection of ethidium bromide into the caudal cerebellar peduncles (CCPs) of adult rats ([Figure 1](#fig1){ref-type="fig"}A). In this model, demyelination occurs within 24 hr of injection and induces OPC proliferation and migration, which peaks at 5 days post-lesion induction (dpl), followed by OPC differentiation, which is ongoing at 14 dpl. Remyelination is completed by 21 dpl. There was a significant increase in proliferating (Ki67-positive) rat endothelial cell antigen 1 (RECA-1)-expressing ECs and a robust proliferative response of platelet-derived growth factor receptor beta (PDGFRb)-expressing PCs within the demyelinated lesion at 5 dpl ([Figures S1](#mmc1){ref-type="supplementary-material"}C and S1D), although the vessel area was not altered between 5 and 21 dpl ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B). In the normal-appearing white matter (NAWM), PCs are restricted to the perivascular region ([Figure 1](#fig1){ref-type="fig"}B). The total number of PDGFRb+ cells within the lesion was significantly increased at 14 dpl compared with NAWM ([Figures 1](#fig1){ref-type="fig"}C and 1D). This was accompanied by the appearance of PDGFRb+ cells away from blood vessels, which, because we cannot be certain of their origin, we defined as pericyte-like cells (PLCs) to distinguish them from PCs close to blood vessels ([Figure 1](#fig1){ref-type="fig"}C). Within the whole PDGFRb+ population (i.e., PCs and PLCs), the proportion of PCs declined during remyelination ([Figure 1](#fig1){ref-type="fig"}E), whereas the percentage of parenchymal PLCs increased and was highest at 14 dpl ([Figure 1](#fig1){ref-type="fig"}F). Consistent with the unaltered density of ECs and PCs during remyelination ([Figures S1](#mmc1){ref-type="supplementary-material"}E and S1F), the EC:PC ratio, crucial for BBB stability ([@bib2]), remained the same ([Figure 1](#fig1){ref-type="fig"}G). At 5 dpl, there were numerous Ki67+ PDGFRb+ cells in the lesion that peaked at 14 dpl but declined thereafter and were absent at 60 dpl ([Figures 1](#fig1){ref-type="fig"}H--1K). By 60 dpl, when the lesion is fully remyelinated, PDGFRb+ cell numbers and localization were similar to that in NAWM, where only PCs and no PLCs were found ([Figures 1](#fig1){ref-type="fig"}C--1G). Staining for desmin, another PC marker, supported these findings ([Figure S4](#mmc1){ref-type="supplementary-material"}A).Figure 1Pericytes React to Demyelination(A) Ethidium bromide-induced demyelinated lesion in the CCP of adult rats.(B) PDGFRb expressing PC and RECA-1+ ECs in NAWM.(C) Proliferating PDGFRb+ cells and ECs (PDGFRb/RECA-1/Ki67) within lesions at 5, 14, and 21 dpl. White arrows indicate proliferating PCs and yellow arrowheads PLCs.(D--K) Quantitative analyses of different PC parameters in response to demyelination.(L) Immunohistochemistry showing the distance of OPCs (Olig2+/APC−), mature oligodendrocytes (Olig2+/APC+), and PDGFRb+ at 14 dpl; yellow arrowheads indicate OPCs and white arrows mature oligodendrocytes. The high-magnification image shows mature oligodendrocytes close to PDGFRb+ cells.(M) The graph displays the distance distribution of OPCs and mature oligodendrocytes from PDGFRb + cells.(C--M) 3 or more animals were analyzed for each time point.(L and M) 150 or more distance measurements were performed from oligodendrocytes to PDGFRb+ cells per animal.Means ± SEM are shown. Data were analyzed by one-way ANOVA followed by Tukey's post hoc test, Student's t test, or chi-square test. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. Scale bars, (B) 20 μm; (C) 50 μm; (D) 50 μm, high-magnification 10 μm; (E) 50 μm, high magnification 10 μm.

We hypothesized that, if PCs and/or PLCs were involved in the differentiation of OPCs into remyelinating oligodendrocytes, then the differentiated cells would tend to be located in close proximity to PDGFRb+ cells. We therefore assessed the distance between Olig2+/adenomatous polyposis coli (APC)− OPCs and Olig2+/APC+ oligodendrocytes to the nearest PDGFRb+ cell at 14 dpl. We found that oligodendrocytes were preferentially located close (i.e., within 10 μm) to PCs, whereas OPCs showed no preferential clustering close to these cells; neither was there clustering of either OPCs or oligodendrocytes close to PLCs ([Figures 1](#fig1){ref-type="fig"}L and 1M; [Figures S1](#mmc1){ref-type="supplementary-material"}G and S1H). These results suggest that PCs and PLCs may have differential roles in modulating OPC function during remyelination.

Impaired Oligodendrocyte Differentiation during Remyelination in PC-Deficient Mice {#sec2.2}
----------------------------------------------------------------------------------

To determine whether CNS-resident PCs influence remyelination, we used *Pdgfb*^ret/ret^ mice, in which a mutation in the retention motif of the *Pdgfb* gene causes a 75%--85% reduction in capillary PC coverage compared with heterozygous littermates ([Figure 2](#fig2){ref-type="fig"}A; [@bib2], [@bib17]). PDGFRb is still expressed in these mice and can still be used as a marker for residual pericytes.Figure 2OPC Differentiation Is affected during Remyelination in *Pdgfb*^ret/ret^ Mice(A and B) Illustrations of decreased PC coverage in *Pdgfb*^ret/ret^ mice (A) and of lysolecithin-induced demyelination (B).(C and J) Mature oligodendrocytes (Olig2+/APC+) and OPCs (Olig2+/APC−) in lesions of control and *Pdgfb*^ret/ret^ mice at 14 dpl (C) and 21dpl (J).(D--G and K--N) Quantitative analyses of oligodendroglia at 14 dpl (D--G) and 21 dpl (K--N).(H and I) In situ hybridization and quantification for PLP of control and *Pdg*fb^ret/ret^ mice at 14 dpl.(O and P) Toluidine blue staining of remyelination in control and *Pdgfb*^ret/ret^ mice at 21 dpl (O) and its quantification by relative ranking analysis (P).Means ± SEM are shown. Data were analyzed by Student's t test or Mann-Whitney *U* test. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. Scale bars, 100 μm.

We first examined myelination in *Pdgfb*^ret/ret^ mice and found that, on post-natal day 12 (P12), the density of mature oligodendrocytes (Olig2+/APC+) was lower and the density of OPCs (Olig2+/APC−) higher than in control mice. However, on P17, no differences were observed in OPC differentiation and myelination ([Figure S2](#mmc1){ref-type="supplementary-material"}).

Following lysolecithin-induced demyelination in the ventral spinal cord white matter (WM), the number of PDGFRb+ increased substantially in both *Pdgfb*^ret/ret^ and control mice. The number of PDGFRb+ cells in *Pdgfb*^ret/ret^ mice at 5 dpl was less than in control mice, and there were fewer PLCs. However, by 14 dpl, the density of PDGFRb+ cells was the same in both groups because of a higher proliferative response of these cells in the *Pdgfb*^ret/ret^ mice ([Figures S3](#mmc1){ref-type="supplementary-material"}A--S3F). No differences were detected in the astrocyte or in the macrophage/microglial response between *Pdgfb*^ret/ret^ mice and control mice ([Figures S3](#mmc1){ref-type="supplementary-material"}G--S3I). Microglia/macrophages showed the same pro-inflammatory and anti-inflammatory cell profile distribution in both groups ([Figures S3](#mmc1){ref-type="supplementary-material"}J--S3L), and no differences were detected in BBB stability in the lesion area ([Figures S3](#mmc1){ref-type="supplementary-material"}M--S3Q).

The total number of Olig2+ cells within the lesion was reduced in *Pdgfb*^ret/ret^ mice compared with controls at 14 dpl. There was no significant difference in the number of Olig2+/APC− OPCs between *Pdgfb*^ret/ret^ and control mice ([Figures 2](#fig2){ref-type="fig"}C and 2E). However, the number of Olig2+/APC+ mature oligodendrocytes was significantly reduced in *Pdgfb*^ret/ret^mice ([Figures 2](#fig2){ref-type="fig"}C, 2F, and 2G). In situ hybridization for proteolipid protein (PLP), a major myelin component, generated consistent results ([Figures 2](#fig2){ref-type="fig"}H and 2I). However, the densities of Olig2+ cells and Olig2+APC+ oligodendrocytes were the same in both groups by 21 dpl ([Figures 2](#fig2){ref-type="fig"}J--2N). No differences were detected in the extent of remyelination, as assessed by ranking analysis of toluidine blue-stained resin sections in which demyelinated and remyelinated axons were discernable ([Figures 2](#fig2){ref-type="fig"}O and 2P).

These data indicate that *Pdgfb*^ret/ret^ mice show a delay in OPC differentiation because of the decreased numbers of PDGFRb+ cells at the earlier stages following demyelination. However, because the PDGFRb+ cell numbers normalize by 14 dpl, this delay does not translate into a decrease in remyelination.

PCs Promote OPC Differentiation and Enhance Remyelination Ex Vivo {#sec2.3}
-----------------------------------------------------------------

We next examined how PCs might directly influence OPC function. We therefore exposed cultured OPCs to PC-conditioned medium (PC-CM) and evaluated the rate of differentiation. MSC-conditioned medium (MSC-CM), previously identified as a strong inducer of OPC differentiation ([@bib14]), was used as a positive control. Primary PCs exhibiting MSCs features, including mesenchymal differentiation potential, were isolated from adult rat brains ([Figure 3](#fig3){ref-type="fig"}A; [Figures S4](#mmc1){ref-type="supplementary-material"}B--S4D). Upon incubation with PC-CM, a higher proportion of OPCs had acquired 2\',3′-cyclic-nucleotide 3′-phosphodiesterase (CNP) and myelin basic protein (MBP) expression at 2 days in vitro (DIV) compared with those exposed to non-conditioned control medium ([Figures 3](#fig3){ref-type="fig"}B--3D). We also found a significantly higher proportion of NG2+/Olig2+ OPCs in the PC-CM-treated cultures ([Figures 3](#fig3){ref-type="fig"}B and 3E). This effect was likely due to an anti-apoptotic effect of the PC-CM because PC-CM significantly decreased the proportion of caspase-3-positive OPCs compared with control conditions ([Figure 3](#fig3){ref-type="fig"}F). Proliferation, assessed by Ki67 staining, was not affected by PC-CM ([Figure 3](#fig3){ref-type="fig"}G).Figure 3PCs Promote OPC Differentiation and Accelerate Remyelination in Demyelinated Organotypic Slices(A) Schematic of the experimental design.(B--E) Fluorescence images (B) displaying CNP+/Olig2+, MBP+/Olig2+, and NG2+/Olig2+ oligodendrocytes at 4 DIV and their respective graphs (C--E).(F and G) PC-CM increases the generation of oligodendrocytes from OPCs. Graphs display (F) the OPC survival rate (NG2+/Caspase+) and (G) the OPC proliferation rate (NG2+/Ki67+) under different conditions.(H) Illustration of lysolecithin-induced demyelination of slice cultures.(I) Images showing axons (NFH+) and myelin (MBP+) of remyelinating cerebellar slices exposed to control medium versus PC-CM at 4, 6, and 8 days post lysolecithin treatment.(J) Quantification of the MBP/NFH ratio shows that PC-CM increases the remyelination rate. 3 or more independent OPC and slice preparations were used.Means ± SEM are shown. Data were analyzed by two-way ANOVA followed by Bonferroni's post hoc test. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. ^∗^ indicates statistical difference for PC-CM and \# for MSC-CM. Scale bars, (B) 100 μm and (I) 50 μm.

We next examined whether PCs can enhance remyelination. We used postnatal rat-derived cerebellar organotypic slice cultures as an ex vivo model of remyelination ([@bib27], [@bib30]). In this model, P10 rat cerebellar slices were demyelinated using lysolecithin ([@bib3]) and then exposed to PC-CM or control medium ([Figure 3](#fig3){ref-type="fig"}H). Remyelination was analyzed at 0, 2, 4, 6, and 8 days after lysolecithin treatment by immunohistochemical staining for MBP and neurofilament heavy chain (NFH). PC-CM significantly enhanced the remyelination rate after lysolecithin-induced demyelination ([Figures 3](#fig3){ref-type="fig"}I and 3J).

PC-Induced OPC Differentiation Is Mediated through Lama2 {#sec2.4}
--------------------------------------------------------

We have previously shown that Lama2 mRNA expression is decreased in the microvessels of *Pdgfb*^ret/ret^ mice compared with control mice ([@bib2]; [Figure 4](#fig4){ref-type="fig"}B). The *Lama2* gene product is highly expressed during remyelination ([@bib31]) and has been shown to modulate OPC function ([@bib23]). Given that the main source of Lama2 within the microvessels is PDGFRb+ cells, as shown by RNA sequencing (RNA-seq) ([@bib13]; [Figure 4](#fig4){ref-type="fig"}A), we investigated whether Lama2 is a mediator of the PC-induced effect on OPC differentiation. RNA in situ hybridization of healthy brain sections revealed a specific expression of Lama2 in cells expressing the PC markers PDGFRb and CD13 ([Figure 4](#fig4){ref-type="fig"}D). In control mice, Lama2 was mainly detected around cell bodies and processes of PCs, whereas *Pdgfb*^ret/ret^ mice had less Lama2 protein expression that, when present, was always associated with residual PCs ([Figure 4](#fig4){ref-type="fig"}E). Cultured PCs also expressed Lama2 ([Figure 4](#fig4){ref-type="fig"}C). Pre-incubation of PC-CM with an anti-Lama2 antibody resulted in a significant decrease in the Olig2+/CNP+ and Olig2+/MBP+ populations compared with PC-CM pre-incubated with a general immunoglobulin G (IgG), reducing OPC differentiation to a level indistinguishable from control conditions ([Figures 4](#fig4){ref-type="fig"}F and 4G). These results were replicated in OPCs exposed to PC-CM harvested from PCs treated with either non-targeting or Lama2 small interfering RNA (siRNA) for 48 hr ([Figures 4](#fig4){ref-type="fig"}H and 4I). Taken together, these data identify Lama2 as a PC-derived molecule that promotes OPC differentiation.Figure 4PC-Derived Lama2 Promotes OPC Differentiation and Is Decreased in *Pdgfb*^ret/ret^ Mice(A) RNA-seq data showing the expression of Lama2 in the microvasculature (mainly consisting of a majority of ECs with very low PC contribution) versus sorted PCs (data extracted from [@bib13]).(B) Downregulation of Lama2 in microvessels of *Pdgfb*^ret/ret^ mice (Affymetrix array data extracted from [@bib13]).(C) Western blot image indicating Lama2 expressed by PCs in vivo (brain) and in vitro.(D) RNA in situ hybridization images showing PC-specific expression of PDGFRb, CD13, and Lama2.(E) Confocal images of CD31/PDGFRb-GFP/Lama2/desmin of *Pdgfb*^ret/+^ × *Pdgfrb*-EGFP mice compared with *Pdgfb*^ret/ret^ × *Pdgfrb*-EGFP indicate PC-specific expression of Lama2 and show a decline of PCs and Lama2 in *Pdg*fb^ret/ret^ mice. Boxed areas represent high-magnification images.(F) Fluorescence images of oligodendrocytes (Olig2+/MBP+) 2 DIV with control medium, PC-CM with IgG, and PC-CM with anti-Lama2-blocking antibody.(G) Graph displaying the percentage of Olig2+/MBP+ cells.(H) Fluorescence images of OPCs in control medium, PC- CM from non-targeting siRNA, and PC Lama2 siRNA-treated-CM.(I) Graph displaying the Olig2+/MBP+ cell population in the presence of the different siRNA-treated PC-CMs. n = 4 mice per group, and 3 or more independent cell preparations were used, except for siRNA experiments, where n = 2.Means ± SEM are shown. Data were analyzed by Student's t test or one-way ANOVA followed by Tukey's post hoc test. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. Scale bars, (C) 5 μm; (D) 100 μm, high-magnification 10 μm; (E) and (G), 50 μm.

Discussion {#sec3}
==========

This work reveals an unidentified role of PCs in CNS regeneration. We show that PCs in the vessel walls respond to demyelination by proliferation. We describe a parenchymal cell population expressing PC markers such as PDGFRb and desmin that appears soon after the induction of demyelination. Although these cells express PC markers, we cannot be certain of their origin, and, therefore, we refer to them as PLCs. Upon demyelination, both PCs and PLCs have a high proliferative response; however, mature oligodendrocytes are preferentially located in higher frequency close to PCs. These data suggest that, even though both populations respond to demyelination, they may have differential roles in their interaction with OPCs during remyelination, which will require further investigation. In mice with a reduced PC density, OPC differentiation is delayed in the demyelinated lesion, resulting in fewer mature oligodendrocytes at 14 dpl. Moreover, exposure to PC-CM accelerated OPC differentiation and enhanced ex vivo remyelination. We identified Lama2 as a key factor responsible for the effect of PCs in promoting OPC differentiation.

In humans, loss of *LAMA2* gene expression causes WM abnormalities, manifested at an early postnatal age, when developmental myelination occurs ([@bib1]). Similarly, a mouse model for Lama2 deficiency (*Lama2*^*−/−*^) shows developmental delays in oligodendrocyte differentiation and the accumulation of OPCs, leading to defects in myelination in the corpus callosum ([@bib6], [@bib23]). Lama2 regulates OPC function through its interaction with dystroglycan ([@bib16]). In the CNS, Lama2 is expressed by PCs and upregulated during OPC differentiation (14 dpl) in a toxin-induced demyelination model ([@bib31]). Lama2 seems to be relevant for PC function because *Lama2*^*−/−*^ mice have decreased microvascular PC coverage associated with BBB defects ([@bib21]). Our data suggest that PC-derived Lama2 has a key role in promoting OPC differentiation because the PC-CM effect in OPCs was inhibited when exposed to an anti-Lama2 antibody or when PCs were treated with Lama2 siRNA. Consistent with this, we observed that OPC differentiation was delayed in adult *Pdgfb*^ret/ret^ mice after lysolecithin-induced demyelination. These findings indicate that PCs provide an appropriate milieu for differentiating OPCs through Lama2.

This study indicates that PC functions are not restricted to vascular homeostasis but, rather, extend to CNS regeneration. This is supported by studies illustrating that PCs respond with high proliferation to acute lesions such as stroke or spinal cord injury (SCI), where they modulate inflammation or the formation of fibrotic scar tissue ([@bib12], [@bib22]). Here we show that, besides stabilizing CNS vasculature and regulating EC function, pericytes also have a high proliferative response following CNS demyelination and directly influence CNS-resident progenitor cell differentiation during remyelination, most likely by secretion of Lama2.

Experimental Procedures {#sec4}
=======================

Animal Work {#sec4.1}
-----------

Animal experiments within this research have been regulated under the Animals (Scientific Procedures) Act 1986 Amendment Regulations 2012 following ethical review by the University of Cambridge Animal Welfare and Ethical Review Body (AWERB) in accordance with United Kingdom Home Office regulations (Project License 70/7715) and in accordance with Austrian laws on animal experimentation and were approved by Austrian regulatory authorities (Permit No. BMWF-66.012/0001-II/3b/2014; license codes BMBF-66-012/0037-WF/V/3b/2014 and BMWF-66.012/0032-WF/V/3b/2015). During this study, 2- to 3-month-old Sprague Dawley rats and 12-week-old *Pdgfb*ret/ret mice (hetero- and homozygous), which were previously described by [@bib2] and [@bib17], were used for toxin-induced demyelination.

Cell Culture {#sec4.2}
------------

Preparation of CNS pericytes was performed following the Dore-Duffy protocol ([@bib8]) with modifications. Rat bone marrow-derived MSCs were prepared as described previously by [@bib24]. OPCs were prepared from neonatal P0--P2 Sprague-Dawley rats, cortices and hippocampi were digested with papain solution, and dissociated cells were seeded into poly-D-lysine-coated T75 flasks. Mixed glial cultures were kept for 11 DIV in medium with DMEM (Gibco) and 10% fetal bovine serum (Biosera). OPCs were isolated as described previously ([@bib20]).

Organotypic Cerebellar Slices {#sec4.3}
-----------------------------

Remyelination of rat cerebellar slices was prepared as described previously ([@bib3]). After 7 DIV, the medium was replaced with organotypic slice medium containing 0.5 mg/mL lysolecithin for 16 hr. After 16 hr, the medium was replaced with PC-conditioned organotypic slice medium and non-conditioned control medium.

Statistical Analyses {#sec4.4}
--------------------

Graphs show mean values ± SEM, and statistical analysis were performed using GraphPad Prism 5.0 (GraphPad) and SPSS 20 (IBM). Parametric one-way ANOVA, Tukey post hoc analyses, Student's t test, or Mann-Whitney *U* tests (when not normally distributed) were used when comparing one parameter. For statistical analysis with two parameters, such as time course experiments with different treatments, two-way ANOVA with Bonferroni post hoc was used. For distance frequency distribution analysis, chi-square test was used ([Figure 1](#fig1){ref-type="fig"}M; [Figures S1](#mmc1){ref-type="supplementary-material"}G and S1H). All experiments were performed as indicated by n in the figure legends. Significance was as follows: p^∗^ \< 0.05, p^∗∗^ \< 0.01, and p^∗∗∗^ \< 0.001.

For further details, see the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.
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